FULC

Fulcrum Therapeutics, Inc.

Price Chart

Latest Quote

$3.83

+0.06 (+1.59%)

Current Price

Previous Close	$3.77
Open	$3.69
Day High	$3.89
Day Low	$3.69
Volume	1,372,008

Fetched: 2026-06-23T18:47:44

Stock Information

Shares Outstanding	66.63M
Total Debt	$5.87M
Cash Equivalents	$333.32M
Net Income	$-76.12M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$255.21M
EPS (TTM)	$-1.15
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-76.24M
Income	$-76.12M
Book/sh	$5.00
Cash/sh	$5.00
Employees	55

Financial Ratios

Quick Ratio	33.97
Current Ratio	34.33
Debt/Eq	1.76

Returns & Margins

ROA	-18.36%
ROE	-27.10%

Ownership

Insider Ownership	3.86%
Institutional Ownership	116.30%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-5.82
P/B	0.77

Analyst Data

Recommendation	hold
Target Price	$5.43

Technical Indicators

SMA20	$4.32
SMA50	$6.08
SMA200	$8.57
RSI	72.85
ATR	0.2304

Shares Float	47.97M
Short Float	12.14%
Short Ratio	14.73
Volatility	2.92
Rel Volume	0.29

Performance History

Week	+9.12%
Month	-41.88%
Quarter	-44.41%
6 Months	-68.50%
YTD	-64.93%
Year	-45.25%
3 Years	+25.99%
5 Years	-54.62%
10 Years	-71.63%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-23	$3.83	1,372,008
2026-06-22	$3.77	2,868,500
2026-06-18	$3.70	6,100,800
2026-06-17	$3.50	10,467,900
2026-06-16	$3.46	6,026,500
2026-06-15	$3.51	3,335,000
2026-06-12	$3.45	1,344,100
2026-06-11	$3.55	2,500,300
2026-06-10	$3.51	2,459,500
2026-06-09	$3.52	3,984,900
2026-06-08	$3.44	3,314,200
2026-06-05	$3.69	3,955,400
2026-06-04	$3.37	4,816,200
2026-06-03	$3.22	5,598,700
2026-06-02	$3.14	32,803,600
2026-06-01	$6.42	3,121,500
2026-05-29	$6.92	391,000
2026-05-28	$6.82	313,600
2026-05-27	$6.78	326,000
2026-05-26	$6.76	369,200

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

📰 Latest News

A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring

Simply Wall St. • 2026-06-05T15:15:30Z

Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks • 2026-06-05T13:35:02Z

FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End

Zacks • 2026-06-03T15:00:00Z

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?

Stocktwits • 2026-06-03T03:04:14Z

This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

Barrons.com • 2026-06-02T16:13:00Z

Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls

The Fly • 2026-06-02T13:43:12Z

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

BioPharma Dive • 2026-06-02T12:08:00Z

FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk

Stocktwits • 2026-06-01T21:50:50Z

Fulcrum Therapeutics Discontinues Sickle Cell Disease Program After US FDA Raises Malignancy Concerns

MT Newswires • 2026-06-01T20:56:27Z

After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)

Zacks • 2026-05-20T13:35:03Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$80,000,000	$2,805,000	$6,342,000
Operating Revenue	$0	$80,000,000	$2,805,000	$6,342,000
Expenses
Total Expenses	$84,769,000	$99,834,000	$113,469,000	$118,476,000
Other Income Expense	$9,889,000	$10,109,000	$13,329,000	$2,263,000
Other Non Operating Income Expenses	$9,889,000	$12,172,000	$13,329,000	$2,690,000
Operating Expense	$84,769,000	$99,834,000	$113,469,000	$118,476,000
General And Administrative Expense	$28,666,000	$36,448,000	$41,668,000	$41,694,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-74,880,000	$-9,725,000	$-97,335,000	$-109,871,000
Normalized Income	$-74,880,000	$-7,662,000	$-97,335,000	$-109,444,000
Net Income From Continuing And Discontinued Operation	$-74,880,000	$-9,725,000	$-97,335,000	$-109,871,000
Total Operating Income As Reported	$-84,769,000	$-21,897,000	$-110,664,000	$-112,561,000
Net Income Common Stockholders	$-74,880,000	$-9,725,000	$-97,335,000	$-109,871,000
Net Income	$-74,880,000	$-9,725,000	$-97,335,000	$-109,871,000
Net Income Including Noncontrolling Interests	$-74,880,000	$-9,725,000	$-97,335,000	$-109,871,000
Net Income Continuous Operations	$-74,880,000	$-9,725,000	$-97,335,000	$-109,871,000
Pretax Income	$-74,880,000	$-9,725,000	$-97,335,000	$-109,871,000
Special Income Charges	$0	$-2,063,000	$0	$-427,000
Operating Income	$-84,769,000	$-19,834,000	$-110,664,000	$-112,134,000
Per Share
Diluted EPS	$-1.18	$-0.16	$-1.59	$-2.44
Basic EPS	$-1.18	$-0.16	$-1.59	$-2.44
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-83,379,000	$-16,178,000	$-108,492,000	$-109,293,000
Total Unusual Items	$0	$-2,063,000	$0	$-427,000
Total Unusual Items Excluding Goodwill	$0	$-2,063,000	$0	$-427,000
Reconciled Depreciation	$1,390,000	$1,593,000	$2,172,000	$2,414,000
EBITDA (Bullshit earnings)	$-83,379,000	$-18,241,000	$-108,492,000	$-109,720,000
EBIT	$-84,769,000	$-19,834,000	$-110,664,000	$-112,134,000
Diluted Average Shares	$63,355,000	$61,984,000	$61,310,000	$44,991,000
Basic Average Shares	$63,355,000	$61,984,000	$61,310,000	$44,991,000
Diluted NI Availto Com Stockholders	$-74,880,000	$-9,725,000	$-97,335,000	$-109,871,000
Restructuring And Mergern Acquisition	$0	$2,063,000	$0	$427,000
Research And Development	$56,103,000	$63,386,000	$71,801,000	$76,782,000
Selling General And Administration	$28,666,000	$36,448,000	$41,668,000	$41,694,000
Other Gand A	$11,338,000	$16,694,000	$16,859,000	$18,206,000
Salaries And Wages	$17,328,000	$19,754,000	$24,809,000	$23,488,000

Fetched: 2026-06-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$349,000,000	$243,034,000	$235,193,000	$198,942,000
Total Assets	$366,284,000	$260,718,000	$257,694,000	$226,685,000
Total Non Current Assets	$8,804,000	$10,795,000	$15,495,000	$19,166,000
Other Non Current Assets	$1,739,000	$1,211,000	$3,103,000	$3,197,000
Current Assets	$357,480,000	$249,923,000	$242,199,000	$207,519,000
Prepaid Assets	$4,104,000	$5,560,000	$3,729,000	$3,517,000
Receivables	$1,070,000	$3,342,000	$2,249,000	$1,081,000
Accrued Interest Receivable	$1,070,000	$1,246,000	$1,712,000	$852,000
Cash Cash Equivalents And Short Term Investments	$352,306,000	$241,021,000	$236,221,000	$202,921,000
Cash And Cash Equivalents	$197,533,000	$58,212,000	$25,563,000	$35,098,000
Cash Equivalents	$197,533,000	$58,212,000	$25,563,000	$35,098,000
Other Receivables	-	$2,096,000	$537,000	$229,000
Accounts Receivable	-	-	-	$0
Debt
Total Debt	$6,443,000	$8,629,000	$10,821,000	$13,423,000
Long Term Debt And Capital Lease Obligation	$4,039,000	$6,443,000	$8,629,000	$10,821,000
Current Debt And Capital Lease Obligation	$2,404,000	$2,186,000	$2,192,000	$2,602,000
Liabilities
Total Liabilities Net Minority Interest	$17,284,000	$17,684,000	$22,501,000	$27,743,000
Total Non Current Liabilities Net Minority Interest	$4,236,000	$6,640,000	$8,826,000	$11,018,000
Other Non Current Liabilities	$197,000	$197,000	$197,000	$197,000
Current Liabilities	$13,048,000	$11,044,000	$13,675,000	$16,725,000
Other Current Liabilities	$258,000	$463,000	$396,000	$105,000
Payables And Accrued Expenses	$10,386,000	$8,395,000	$11,087,000	$13,084,000
Payables	$1,592,000	$1,164,000	$2,757,000	$3,638,000
Accounts Payable	$1,592,000	$1,164,000	$2,757,000	$3,638,000
Current Deferred Liabilities	-	-	$0	$934,000
Non Current Deferred Liabilities	-	-	-	$0
Equity
Common Stock Equity	$349,000,000	$243,034,000	$235,193,000	$198,942,000
Total Equity Gross Minority Interest	$349,000,000	$243,034,000	$235,193,000	$198,942,000
Stockholders Equity	$349,000,000	$243,034,000	$235,193,000	$198,942,000
Gains Losses Not Affecting Retained Earnings	$174,000	$130,000	$-136,000	$-797,000
Other Equity Adjustments	$174,000	$130,000	$-136,000	$-797,000
Retained Earnings	$-594,278,000	$-519,398,000	$-509,673,000	$-412,338,000
Other
Ordinary Shares Number	$66,578,891	$53,968,303	$61,915,367	$52,099,211
Share Issued	$66,578,891	$53,968,303	$61,915,367	$52,099,211
Tangible Book Value	$349,000,000	$243,034,000	$235,193,000	$198,942,000
Invested Capital	$349,000,000	$243,034,000	$235,193,000	$198,942,000
Working Capital	$344,432,000	$238,879,000	$228,524,000	$190,794,000
Capital Lease Obligations	$6,443,000	$8,629,000	$10,821,000	$13,423,000
Total Capitalization	$349,000,000	$243,034,000	$235,193,000	$198,942,000
Additional Paid In Capital	$943,037,000	$762,248,000	$744,940,000	$612,025,000
Capital Stock	$67,000	$54,000	$62,000	$52,000
Common Stock	$67,000	$54,000	$62,000	$52,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$4,039,000	$6,443,000	$8,629,000	$10,821,000
Current Capital Lease Obligation	$2,404,000	$2,186,000	$2,192,000	$2,602,000
Current Accrued Expenses	$8,794,000	$7,231,000	$8,330,000	$9,446,000
Net PPE	$7,065,000	$9,584,000	$12,392,000	$15,969,000
Accumulated Depreciation	$-15,647,000	$-14,257,000	$-12,760,000	$-10,662,000
Gross PPE	$22,712,000	$23,841,000	$25,152,000	$26,631,000
Leases	$7,121,000	$7,121,000	$7,102,000	$7,102,000
Other Properties	$14,399,000	$15,528,000	$16,858,000	$18,120,000
Machinery Furniture Equipment	$1,192,000	$1,192,000	$1,192,000	$1,378,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$154,773,000	$182,809,000	$210,658,000	$167,823,000
Treasury Shares Number	-	-	$0	-
Current Deferred Revenue	-	-	$0	$934,000
Construction In Progress	-	-	$0	$31,000
Treasury Stock	-	-	-	$0
Non Current Deferred Revenue	-	-	-	$0

Fetched: 2026-06-22

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-60,379,000	$-2,496,000	$-91,473,000	$-99,013,000
Operating Activities
Operating Cash Flow	$-60,065,000	$-2,218,000	$-90,965,000	$-97,050,000
Cash Flow From Continuing Operating Activities	$-60,065,000	$-2,218,000	$-90,965,000	$-97,050,000
Investing Activities
Capital Expenditure	$-314,000	$-278,000	$-508,000	$-1,963,000
Investing Cash Flow	$30,719,000	$32,230,000	$-36,692,000	$12,413,000
Cash Flow From Continuing Investing Activities	$30,719,000	$32,230,000	$-36,692,000	$12,413,000
Financing Activities
Issuance Of Capital Stock	$164,500,000	$0	$117,345,000	$80,804,000
Financing Cash Flow	$168,667,000	$2,746,000	$118,122,000	$84,323,000
Cash Flow From Continuing Financing Activities	$168,667,000	$2,746,000	$118,122,000	$84,323,000
Net Common Stock Issuance	$164,500,000	$0	$117,345,000	$80,804,000
Common Stock Issuance	$164,500,000	$0	$117,345,000	$80,804,000
Other
End Cash Position	$198,734,000	$59,413,000	$26,655,000	$36,190,000
Beginning Cash Position	$59,413,000	$26,655,000	$36,190,000	$36,504,000
Changes In Cash	$139,321,000	$32,758,000	$-9,535,000	$-314,000
Proceeds From Stock Option Exercised	$4,167,000	$2,746,000	$777,000	$3,519,000
Net Investment Purchase And Sale	$31,033,000	$32,508,000	$-36,184,000	$14,376,000
Sale Of Investment	$211,253,000	$211,102,000	$158,708,000	$165,529,000
Purchase Of Investment	$-180,220,000	$-178,594,000	$-194,892,000	$-151,153,000
Net PPE Purchase And Sale	$-314,000	$-278,000	$-508,000	$-1,963,000
Purchase Of PPE	$-314,000	$-278,000	$-508,000	$-1,963,000
Change In Working Capital	$3,910,000	$-4,248,000	$-4,613,000	$-3,094,000
Change In Other Working Capital	$-743,000	$-700,000	$-1,649,000	$-4,149,000
Change In Other Current Assets	$-528,000	$2,001,000	$94,000	$-1,562,000
Change In Payables And Accrued Expense	$1,453,000	$-2,625,000	$-1,678,000	$-621,000
Change In Accrued Expense	$1,025,000	$-1,032,000	$-825,000	$555,000
Change In Payable	$428,000	$-1,593,000	$-853,000	$-1,176,000
Change In Account Payable	$428,000	$-1,593,000	$-853,000	$-1,176,000
Change In Prepaid Assets	$1,632,000	$-1,365,000	$-1,072,000	$-170,000
Change In Receivables	$2,096,000	$-1,559,000	$-308,000	$3,408,000
Stock Based Compensation	$12,468,000	$14,554,000	$14,802,000	$13,350,000
Amortization Of Securities	$-2,953,000	$-4,392,000	$-5,991,000	$152,000
Depreciation Amortization Depletion	$1,390,000	$1,593,000	$2,172,000	$2,414,000
Depreciation And Amortization	$1,390,000	$1,593,000	$2,172,000	$2,414,000
Depreciation	$1,390,000	$1,593,000	$2,172,000	$2,414,000
Net Income From Continuing Operations	$-74,880,000	$-9,725,000	$-97,335,000	$-109,872,000
Changes In Account Receivables	-	-	$0	$2,500,000
Repayment Of Debt	-	-	-	$0
Net Issuance Payments Of Debt	-	-	-	$0
Net Long Term Debt Issuance	-	-	-	$0
Long Term Debt Payments	-	-	-	$0
Interest Paid Supplemental Data	-	-	-	-

Fetched: 2026-06-22